Recent progress in the understanding of relaxin family peptides and their receptors

Research output: Contribution to journalEditorialOtherpeer-review

Abstract

The 7th International Conference in the series on ‘Relaxin and related peptides’ covered all aspects of the basic biology of relaxin (human H2-relaxin), its potential clinical applications and the current clinical trials in acute heart failure. Additionally, the evolution, chemistry, pharmacology, physiology and potential clinical applications of the other members of the relaxin peptide family including, relaxin-3, insulin-like peptide 3 (INSL3) and INSL5 were also covered. Relaxin pharmacology has reached an important stage with the recombinant form of the peptide now in extended Phase III clinical trials for the treatment of acute heart failure (see articles by Unemori 2017 and Sarwar et al., 2017) having been identified as one of few approaches with the potential to improve cardiovascular and all-cause mortality in this condition.
Original languageEnglish
Pages (from-to)915-920
Number of pages6
JournalBritish Journal of Pharmacology
Volume174
Issue number10
DOIs
Publication statusPublished - 2017

Cite this

@article{94aba06e56334873b8f278556a40ba98,
title = "Recent progress in the understanding of relaxin family peptides and their receptors",
abstract = "The 7th International Conference in the series on ‘Relaxin and related peptides’ covered all aspects of the basic biology of relaxin (human H2-relaxin), its potential clinical applications and the current clinical trials in acute heart failure. Additionally, the evolution, chemistry, pharmacology, physiology and potential clinical applications of the other members of the relaxin peptide family including, relaxin-3, insulin-like peptide 3 (INSL3) and INSL5 were also covered. Relaxin pharmacology has reached an important stage with the recombinant form of the peptide now in extended Phase III clinical trials for the treatment of acute heart failure (see articles by Unemori 2017 and Sarwar et al., 2017) having been identified as one of few approaches with the potential to improve cardiovascular and all-cause mortality in this condition.",
author = "Summers, {R J}",
year = "2017",
doi = "10.1111/bph.13778",
language = "English",
volume = "174",
pages = "915--920",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "10",

}

Recent progress in the understanding of relaxin family peptides and their receptors. / Summers, R J.

In: British Journal of Pharmacology, Vol. 174, No. 10, 2017, p. 915-920.

Research output: Contribution to journalEditorialOtherpeer-review

TY - JOUR

T1 - Recent progress in the understanding of relaxin family peptides and their receptors

AU - Summers, R J

PY - 2017

Y1 - 2017

N2 - The 7th International Conference in the series on ‘Relaxin and related peptides’ covered all aspects of the basic biology of relaxin (human H2-relaxin), its potential clinical applications and the current clinical trials in acute heart failure. Additionally, the evolution, chemistry, pharmacology, physiology and potential clinical applications of the other members of the relaxin peptide family including, relaxin-3, insulin-like peptide 3 (INSL3) and INSL5 were also covered. Relaxin pharmacology has reached an important stage with the recombinant form of the peptide now in extended Phase III clinical trials for the treatment of acute heart failure (see articles by Unemori 2017 and Sarwar et al., 2017) having been identified as one of few approaches with the potential to improve cardiovascular and all-cause mortality in this condition.

AB - The 7th International Conference in the series on ‘Relaxin and related peptides’ covered all aspects of the basic biology of relaxin (human H2-relaxin), its potential clinical applications and the current clinical trials in acute heart failure. Additionally, the evolution, chemistry, pharmacology, physiology and potential clinical applications of the other members of the relaxin peptide family including, relaxin-3, insulin-like peptide 3 (INSL3) and INSL5 were also covered. Relaxin pharmacology has reached an important stage with the recombinant form of the peptide now in extended Phase III clinical trials for the treatment of acute heart failure (see articles by Unemori 2017 and Sarwar et al., 2017) having been identified as one of few approaches with the potential to improve cardiovascular and all-cause mortality in this condition.

U2 - 10.1111/bph.13778

DO - 10.1111/bph.13778

M3 - Editorial

VL - 174

SP - 915

EP - 920

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 10

ER -